MCRB (Seres Therapeutics) Cyclically Adjusted Revenue per Share: $17.82 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MCRB Seres Therapeutics Inc MCRB
13 GF Score
Price $4.76
! 5 Warning Signs
View Full Analysis

What is Seres Therapeutics Cyclically Adjusted Revenue per Share?

Seres Therapeutics MCRB -4.80% 13 Cyclically Adjusted Revenue per Share is $17.82 as of Jun. 2026. GuruFocus rates MCRB with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Seres Therapeutics's adjusted revenue per share for the three months ended in Jun. 2026 was $0.076. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $17.82 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-27), Seres Therapeutics's current stock price is $4.76. Seres Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $17.82. Seres Therapeutics's Cyclically Adjusted PS Ratio of today is 0.27.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Seres Therapeutics was 0.90. The lowest was 0.25. And the median was 0.44.


Seres Therapeutics  (NAS:MCRB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Seres Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.76/17.82
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Seres Therapeutics was 0.90. The lowest was 0.25. And the median was 0.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Seres Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Seres Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Seres Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seres Therapeutics Cyclically Adjusted Revenue per Share Chart

Seres Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 17.78

Seres Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 17.78 17.87 17.82

MCRB vs IBO, TIL, ATYR: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Seres Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seres Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's Cyclically Adjusted PS Ratio falls into.


MCRB
13GF Score
Seres Therapeutics Inc MCRB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seres Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Seres Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.076/333.9520*333.9520
=0.076

Current CPI (Jun. 2026) = 333.9520.

Seres Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6.469 241.428 8.948
201612 1.504 241.432 2.080
201703 1.494 243.801 2.046
201706 1.492 244.955 2.034
201709 11.365 246.819 15.377
201712 1.508 246.524 2.043
201803 1.955 249.554 2.616
201806 2.269 251.989 3.007
201809 4.439 252.439 5.872
201812 5.200 251.233 6.912
201903 3.569 254.202 4.689
201906 5.552 256.143 7.239
201909 2.011 256.759 2.616
201912 2.173 256.974 2.824
202003 2.313 258.115 2.993
202006 1.649 257.797 2.136
202009 0.339 260.280 0.435
202012 3.842 260.474 4.926
202103 1.250 264.877 1.576
202106 1.148 271.696 1.411
202109 26.690 274.310 32.493
202112 1.805 278.802 2.162
202203 0.324 287.504 0.376
202206 0.264 296.311 0.298
202209 0.562 296.808 0.632
202212 -0.983 296.797 -1.106
202303 -0.083 301.836 -0.092
202306 19.481 305.109 21.323
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.085 324.054 0.088
202603 0.037 330.213 0.037
202606 0.076 333.952 0.076

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $17.82 mean?
Seres Therapeutics (MCRB) has a Cyclically Adjusted Revenue per Share of $17.82 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Seres Therapeutics and its competitors.
Is Seres Therapeutics' Cyclically Adjusted Revenue per Share too high?
Seres Therapeutics' current Cyclically Adjusted Revenue per Share is $17.82. Overall, Seres Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Seres Therapeutics' Cyclically Adjusted Revenue per Share compare to IBO and TIL?
Seres Therapeutics' Cyclically Adjusted Revenue per Share of $17.82 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Seres Therapeutics and its competitors. Seres Therapeutics's current Cyclically Adjusted Revenue per Share is $17.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seres Therapeutics stock overvalued right now?
Seres Therapeutics (MCRB) has a current Cyclically Adjusted Revenue per Share of $17.82. The current Cyclically Adjusted Revenue per Share is $17.82. Seres Therapeutics' overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Seres Therapeutics (MCRB), the current Cyclically Adjusted Revenue per Share is $17.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seres Therapeutics Business Description

Other Exchanges 1S90:Germany
Address 101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
13GF Score

Get the complete analysis for MCRB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.76
Price